aTyr Pharma Inc. provided an update on corporate developments. The company completed patient dosing for Phase 1b/2 trial for Resolaris in adult FSHD patients. The company announced that it has completed patient dosing for its Phase 1b/2 trial for Resolaris in adult FSHD patients and is in the process of database curation and analysis.

The company expects to report data at approximately the end of the first quarter of 2016. The study is a double-blind, placebo-controlled, multiple ascending dose trial at multiple sites in the European Union and United States, and is designed to evaluate safety, tolerability, pharmacokinetics and the biological activity of Resolaris in adult patients with FSHD; first patients dosed in Phase 1b/2 trial of Resolaris in patients with LGMD2B. The first patients have been dosed in the recently initiated Phase 1b/2 trial of Resolaris in patients with LGMD2B.

The international trial is an open-label, intra-patient dose escalation study designed to assess the safety, tolerability, immunogenicity and activity of Resolaris in adult patients with LGMD2B and adult patients with FSHD. The trial will further augment the company's blinded Phase 1b/2 clinical trial of Resolaris in adult patients with FSHD and inform subsequent later-stage trial considerations; started process development for GMP manufacturing in E. coli and commenced preclinical IND-enabling studies for second IND candidate. For aTyr's second IND candidate, iMod.Fc, the company started process development for GMP manufacturing in E. coli, as well as preclinical IND-enabling studies.

iMod.Fc represents the first, engineered Physiocrine-based product candidate. It is based on an immuno- and fibro-modulating Physiocrine domain fused to an Fc region of a human antibody. iMod.Fc has shown promising activity in a well-established preclinical rodent model of lung inflammation and pulmonary fibrosis; anticipating initiation of clinical program in rare pulmonary diseases with an immune component (RPIC).

aTyr plans to initiate a clinical program in RPIC in patients with interstitial lung disease (ILD). Later this year, the company will make a determination as to whether to move forward with an exploratory Phase 1b/2 trial for Resolaris (by the end of 2016) and/or iMod.Fc (in 2017) in one or more ILD indications.